{"id":"iopamidol-300-contrast","safety":{"commonSideEffects":[{"rate":null,"effect":"Contrast-induced nephropathy"},{"rate":null,"effect":"Allergic reaction (mild to severe)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Flushing and warmth sensation"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iopamidol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. It is administered intravenously and distributes throughout the vascular system and extracellular space, allowing enhanced visualization of blood vessels, organs, and tissues during angiography, CT, and other imaging procedures. The non-ionic formulation reduces osmolality compared to ionic agents, lowering the risk of adverse reactions.","oneSentence":"Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:08.747Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contrast enhancement for angiography and vascular imaging"},{"name":"Contrast enhancement for computed tomography (CT) imaging"},{"name":"Contrast enhancement for urography and other radiographic procedures"}]},"trialDetails":[{"nctId":"NCT04504331","phase":"PHASE1","title":"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer","status":"TERMINATED","sponsor":"Jennifer Lee Caswell-Jin","startDate":"2020-10-13","conditions":"Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer","enrollment":4},{"nctId":"NCT07363759","phase":"NA","title":"ISOVUE Comparative Trial","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2019-04-11","conditions":"Lumbar Degenerative Disease, Lumbar Degenerative Disc Disease, Degenerative Spine","enrollment":56},{"nctId":"NCT03973177","phase":"PHASE4","title":"Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-05-24","conditions":"Pain, Chronic","enrollment":""},{"nctId":"NCT03789227","phase":"NA","title":"CT-guided Ablation of the Ganglion Impar for Pelvic Tumors: Comparethe Addition of Ketorolac or Dexamethasone","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2018-07-01","conditions":"Pain, Chronic","enrollment":120},{"nctId":"NCT02433665","phase":"NA","title":"Customized Contrast Media Dose Clinical Trial","status":"TERMINATED","sponsor":"Duke University","startDate":"2015-08","conditions":"CT of the Abdomen and Pelvis With Contrast Material","enrollment":166},{"nctId":"NCT02467075","phase":"PHASE4","title":"Double-Blind Placebo-Controlled CIN Trial","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2015-07","conditions":"Acute Kidney Injury","enrollment":1},{"nctId":"NCT02291718","phase":"PHASE4","title":"Thoracoabdominal Arortic CTA Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-01","conditions":"Thoracic Aortic Aneurysm","enrollment":150},{"nctId":"NCT00209417","phase":"PHASE4","title":"Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2005-06","conditions":"Renal Insufficiency, Diabetes Mellitus","enrollment":656},{"nctId":"NCT01672996","phase":"PHASE1, PHASE2","title":"Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2012-07","conditions":"Healthy","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":278,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Iopamidol 300 (Contrast)","genericName":"Iopamidol 300 (Contrast)","companyName":"University of Michigan","companyId":"university-of-michigan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}